Index
973
contraindications and cautions, 195,
197
drug–drug interactions, 198
pharmacokinetics, 195
protective drugs, 198
therapeutic actions and indications,
195
antimetabolites, 190, 200–204
adverse effects, 203
care considerations, 204
contraindications and cautions, 203
drug–drug interactions, 204
pharmacokinetics, 203
therapeutic actions and indications,
200, 202
antineoplastic antibiotics, 205–208
adverse effects, 207
care considerations, 208
contraindications and cautions, 207
drug–drug interactions, 207
pharmacokinetics, 207
therapeutic actions and indications,
205
breast cancer, 217–218
cancer, 190–192
causes, 192
types of, 192
cancer cell-specific agents, 191,
218–220
care considerations, 222
protein tyrosine kinase inhibitors,
218, 220
cell kill theory, 193
children, 194
hormones and hormone modulators,
191, 212–216
adverse effects, 215
care considerations, 216
contraindications and cautions, 212
drug–drug interactions, 215
pharmacokinetics, 212
therapeutic actions and indications,
212
miscellaneous agents, 191, 222–223
mitotic inhibitors, 191, 209–212
adverse effects, 210
care considerations, 211–212
contraindications and cautions, 210
drug–drug interactions, 210–211
pharmacokinetics, 210
therapeutic actions and indications,
210
older adults, 194
sites of action, 193
Antiparkinsonism agents, 372–383
adjunctive agents, 382–383
adults, 375
anticholinergic agents, 379–381
adverse effects, 380
care considerations, 381
contraindications and cautions, 380
drug–drug interactions, 380–381
pharmacokinetics, 380
therapeutic actions and indications,
379–380
children, 375
dopaminergic agents, 372, 374–378
adverse effects, 376
care considerations, 377
contraindications and cautions, 376
drug–drug interactions, 376
pharmacokinetics, 376
therapeutic actions and indications,
374, 376
older adults, 375
Parkinson disease and parkinsonism,
372, 373–374
pathophysiology, 373
treatment, 374
Antiplatelet agents, 750, 751, 755–756,
758–759
adverse effects, 758–759
care considerations, 759
contraindications and cautions, 758
drug–drug interactions, 759
pharmacokinetics, 758
therapeutic actions and indications, 758
Antiprotozoal agents, 163–176
adults, 164
adverse effects, 173
antimalarials, 163, 166–170
adverse effects, 168–169
care considerations, 169–170
combination drugs, 168
contraindications and cautions, 168
cultural considerations, 169
drug–drug interactions, 169
pharmacokinetics, 167–168
therapeutic actions and indications,
166–167
care considerations, 174
children, 164
contraindications and cautions,
172–173
drug–drug interactions, 173–174
malaria, 163, 164–166
life cycle of
Plasmodium
, 165–166
miscellaneous protozoal infections,
170–172
agents for, 172–174
amoebiasis, 163, 170–171
care considerations, 174
cinchonism, 163
giardiasis, 163, 172
leishmaniasis, 163, 171
Pneumocystis carinii
pneumonia, 163,
172
trichomoniasis, 163, 172
trypanosomiasis, 163, 172
older adults, 164
pharmacokinetics, 172
therapeutic actions and indications, 172
Antipsychotic/neuroleptic drugs, 334,
336–342
adverse effects, 341
care considerations, 342
contraindications and cautions, 340
critical thinking scenario, 343–344
cultural considerations, 340
drug–drug interactions, 341
pharmacokinetics, 339
therapeutic actions and indications, 339
Antipyretic, 240, 241
Antirheumatic drugs, 253–255
adverse effects, 254
contraindications and cautions, 254
drug–drug interactions, 254–255
pharmacokinetics, 254
therapeutic actions and indications, 254
Antiseizure agents, 352–369
adults, 354
altered metabolism, 354
children, 354
drugs for treating generalised seizures,
352, 355–363
barbiturates and barbiturate-like
drugs, 352, 357, 358–359
benzodiazepines, 352, 357, 359–360
care considerations, 362–363
hydantoins, 352, 356–358
succinimides, 352, 357, 360–361
drugs for treating partial seizures, 352,
365–369
adverse effects, 368
care considerations, 368–369
contraindications and cautions, 367
drug–drug interactions, 368
pharmacokinetics, 367
therapeutic actions and indications,
365, 367
nature of seizures, 353–355
absence seizure, 352, 353, 355
classification, 353–355
generalised, 352, 355
partial, 352, 355
older adults, 354
Antispasmodics, 819, 824–826
Antithrombin III, 754, 756, 759–760
Antithymocyte immune globulin, 286
Antithyroid agents, 552, 557, 560–562
adverse effects, 561
care considerations, 561–562
contraindications and cautions,
560–561
drug–drug interactions, 561
pharmacokinetics, 560
therapeutic actions and indications, 560
Antitoxins, 272, 273, 282, 285, 286–287
Antituberculosis drugs, 118
Antitussives, 842, 843–846
adverse effects, 845
care considerations, 845–846
contraindications and cautions, 845
drug–drug interactions, 845
pharmacokinetics, 845
therapeutic actions and indications, 845
Antivenins, 272, 273, 285, 286–287
Antiviral agents, 126–147
adults, 128
antihepatitis B and C agents, 144–146
adverse effects, 145
care considerations, 146
contraindications and cautions, 145
drug–drug interactions, 145
pharmacokinetics, 144–145
therapeutic actions and indications,
144
children, 128
